Author Archives: admin

Cell Transplantatio Therapy Market Global Research and Analysis 2020 – Owned

By adminAugust 6, 2020Stell Cell Research

Global Cell Transplantatio Therapy Market research report published bymarket insight reportsexplores the current outlook in global and key regions from the perspective of Major Players, Countries, Product types and end industries. This report analyzes top players in the global market and divides the Market into several parameters.

This Cell Transplantatio Therapy Market research report identifies the competitive landscape of industries to understand the competition at International level. This report study describes the projected growth of the global market for the years from 2020 to 2025. This research report has been aggregated on the basis of static and dynamic aspects of the businesses.

Click Here to Get Sample PDF Copy of Latest Research on Cell Transplantatio TherapyMarket 2020:

https://www.marketinsightsreports.com/reports/08052204047/global-cell-transplantatio-therapy-market-growth-status-and-outlook-2020-2025/inquiry?Mode=18

The prominent players in the Global Cell Transplantatio Therapy Market:

Gilead Sciences, Guanhao Biotech, Novartis, Vericel Corporation, Vcanbio, Osiris, Beike Biotechnology, Fujifilm Cellular Dynamics, Golden Meditech, JCR Pharmaceuticals and Others.

It further provides the profile reviews of the leading participants, their overall market shares in the global market, business strategies they have adopted, and the latest developments in their respective business in a bid to enhance the decision-making capability of the readers.

The Cell Transplantatio Therapy market can be divided based on product types and Its sub-type, major applications and Third Party usage area, and important regions.

This report segments the Global Cell Transplantatio Therapy Market on the basis ofTypesare:

Stem Cell

Non-Stem Cell

On the basis ofApplication,the Global Cell Transplantatio Therapy Market is segmented into:

Hospitals

Clinics

Others

SPECIAL OFFER: AVAIL UPTO 20% DISCOUNT ON THIS REPORT:

https://www.marketinsightsreports.com/reports/08052204047/global-cell-transplantatio-therapy-market-growth-status-and-outlook-2020-2025/discount?Mode=18

Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), and market share and growth rate of Cell Transplantatio Therapy Market these regions, from 2020 to 2025 (forecast), coveringNorth America, Europe, China, Japan, Southeast Asia, India, North America(USA, Canada and Mexico)Europe(Germany, France, UK, Russia and Italy)AsiaPacific(China, Japan, Korea, India and Southeast).

Significant Features, those are under Offering and Key Highlights of the Reports:

Detailed overview of Cell Transplantatio Therapy Market Changing market dynamics of the industry In-depth market segmentation by Type, Application, etc. Historical, current and projected market size in terms of volume and value Recent industry trends and developments Competitive landscape of Cell Transplantatio Therapy Market Strategies of key players and product offerings Potential and niche segments/regions exhibiting promising growth

The research includes historic data from 2015 to 2019 and forecasts until 2025 which makes the report an invaluable resource for industry executives, marketing, sales and product managers, consultants, analysts and stakeholders looking for key industry data in readily accessible documents with clearly presented tables and graphs.

Finally, the Cell Transplantatio Therapy market report offers a complete and detailed study of global Cell Transplantatio Therapy market by using numerous analytical tools and models such as SWOT analysis, investment return analysis, and porters five forces analysis which are useful for beginners to access the upcoming opportunities. After exploring the market insights through primary and secondary research methodologies, if anything is required except than this, market insight reports will provide customization as per specific demands.

Click the link to Purchase This Full Report @:

https://www.marketinsightsreports.com/report/purchase/08052204047?mode=su?Mode=18

We also offer customization on reports based on specific client requirement:

1- Freecountry level analysis forany 5 countriesof your choice.

2-FreeCompetitive analysis ofany 5 key market players.

3-Free40 analyst hoursto cover any other data points.

Note:- All the reports that we list have been tracking the impact of COVID-19 the market. Both upstream and downstream of the entire supply chain has been accounted for while doing this. Also, where possible, we will provide an additional COVID-19 update supplement/report to the report in Q3, please check for with the sales team.

Read the original:
Cell Transplantatio Therapy Market Global Research and Analysis 2020 - Owned

Future Technological Prospects of Stem Cell Assay Market To 2030 – Owned

By adminAugust 6, 2020Stem Cell Medicine

The research report published by PROPHECY MARKET INSIGHTS encompasses an evaluation of the market, including growth rate, current scenario, and volume inflation prospects, based on DROT and Porters Five Forces analyses. The market study pitches light on the various factors that are projected to impact the overall market dynamics of the Stem Cell Assay market over the forecast period (2019-2029).

The predictions mentioned in the Stem Cell Assay market report have been derived using proven research techniques, assumptions and methodologies. This market report states the overview, historical data along with size, share, growth, demand, and revenue of the global industry.

Stakeholders Benefit:

The report on the Stem Cell Assay market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have been included in the report.

Pandemic offer for our customers: Purchase this Report now by availing up to 40% Discount and free consultation. Limited period offer.

Get Sample Copy of This Report @ https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/3910

We dont know what lies ahead of this COVID-19 Pandemic crises. Our analysis involves the detailed study of the market taking into consideration the impact pandemic situation. We will be grateful if you get in touch with us so that we can understand your exact requirement and we can provide you an exhaustive coverage of the impact of the current situation on the market. We also provide a customized report as per your requirement.

Segmentation Overview:

Global Stem Cell Assay Market, By Type:

Global Stem Cell Assay Market, By Kit:

Global Stem Cell Assay Market, By Detection:

Global Stem Cell Assay Market, By Instruments:

Global Stem Cell Assay Market, By Application:

Global Stem Cell Assay Market, By End User:

The Stem Cell Assay research study comprises 100+ market data Tables, Graphs & Figures, Pie Chat to understand detailed analysis of the market. The predictions estimated in the market report have been resulted in using proven research techniques, methodologies, and assumptions. This Stem Cell Assay market report states the market overview, historical data along with size, growth, share, demand, and revenue of the global industry.

Regional and Country- level Analysis:

Different geographical areas are studied deeply and an economic scenario has been offered to support new entrants, leading market players, and investors to regulate emerging economies. The top producers and consumers focus on production, product capacity, value, consumption, growth opportunity, and market share in these key regions, covering

Australia, New Zealand, Rest of Asia-Pacific

Pandemic offer for our customers: Purchase this Report now by availing up to 40% Discount and free consultation. Limited period offer.

Request discount @ https://www.prophecymarketinsights.com/market_insight/Insight/request-discount/3910

Key Questions Answered in Report:

Competitive landscape Analysis provides mergers and acquisitions, collaborations along with new product launches, heat map analysis, and market presence and specificity analysis.

The comprehensive list of Key Market Players along with their market overview, product protocol, key highlights, key financial issues, SWOT analysis, and business strategies. The report dedicatedly offers helpful solutions for players to increase their clients on a global scale and expand their favour significantly over the forecast period. The report also serves strategic decision-making solutions for the clients.

Stem Cell AssayMarket Key Players:

GE Healthcare, Promega Corporation, Thermo Fisher Scientific Inc., Merck KGaA, Cell Biolabs, Inc., Hemogenix, STEMCELL Technologies Inc., Bio-Rad Laboratories Inc., R&D Systems Inc., and Cellular Dynamics International Inc.

The study analyses the manufacturing and processing requirements, project funding, project cost, project economics, profit margins, predicted returns on investment, etc. With the tables and figures, the report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

About us:

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

Mr Alex (Sales Manager)

Prophecy Market Insights

Phone: +1 860 531 2701

Email: [emailprotected]

Read this article:
Future Technological Prospects of Stem Cell Assay Market To 2030 - Owned

Biobanks Market Projected to be Resilient During 2025 Owned – Owned

By adminAugust 6, 2020Stem Cell Medicine

Global Biobanks Market: Overview

The global biobanks market owes its conception to the rising need for replacement organs and the steady advancement in the replacement and transfusion technologies regarding a number of bodily substances. Though the technology and need to store organs and other bio-entities had been available for a long time, the global biobanks market took on a more important role in the healthcare sector following the increasing research in genomics. In the new millennium, the development of the personalized medicine field has been the vital driver for the global biobanks market. The likely advancement of the latter, thanks to helpful government regulations, is likely to make the crucial difference for the global biobanks market in the near future.

The steady technological advancement in the healthcare sector in the last few decades has now led to a scenario where the full potential of biobanks can be harnessed. As a result, the global biobanks market is projected to exhibit steady growth over the coming years.

Global Biobanks Market: Key Trends

The rising interest in personalized medicine is the prime driver for the global biobanks market. Personalized medicine has only become a viable branch of modern medicine after steady research in genomics and the way various patients react to various medicines. The biobanks market has thus come into the spotlight thanks to their role as a steady supplier of human biomaterials for research as well as direct application. The increasing research in genomics following the findings of the Human Genome Project is thus likely to remain a key driver for the global biobanks market in the coming years.

The utilization of biobanks in stem cell research has been hampered in several regions by ethical concerns regarding the origin of stem cells. Nevertheless, the potential of stem cells in the healthcare sector is immense, and is likely to have a decisive impact on the trajectory of the global biobanks market in the coming years. Many countries have, in recent years, adopted a supportive stance towards stem cell research, aiding the growth of the biobanks market. Continued government support is thus likely to remain vital for the global biobanks market in the coming years.

Global Biobanks Market: Market Potential

The leading role of the U.S. in the global biobanks market is unlikely to change in the coming years. The easy availability of government-supported healthcare infrastructure and the presence of several industry giants in the region has driven the biobanks market in the U.S.

Northwell Health, the largest healthcare provider in New York State, earlier in 2017 initiated a new biobank aimed at creating precision therapies against various types of cancer. Launched in collaboration with Indivumed, the biobank will provide catalogued biomaterials for research into lung, colorectal, breast, and pancreatic cancer. This would enable targeted, gene-specific studies of a variety of cancer samples, leading to a more comprehensive understanding of cancer. Such well-funded collaboration efforts are crucial for the developing biobanks market.

Global Biobanks Market: Geographical Dynamics

Led by the fertile healthcare research scenario in the U.S., North America is likely to retain a dominant share in the global biobanks market in the coming years. Steady support from institutes such as the NIH is likely to be vital for the North America biobanks market.

Emerging Asia Pacific economies such as India and China could emerge with a significant share in the global biobanks market in the coming years. The healthcare sector in both countries has received steady public or private funding in the last few years. India is also a global leader in medical tourism and is likely to receive an increasing number of patients in the coming years, leading to promising prospects for the global biobanks market in the region.

Global Biobanks Market: Competitive Dynamics

Due to the dynamic nature of the global biobanks market, with advancements in diagnostic fields often determining the direction of the market, the market is heavily fragmented. It is likely to retain a significant degree of fragmentation in the coming years thanks to the diversity in the application segments of the biobanks market. The leading players in the global biobanks market includeBioCision, Tecan Group, VWR, Beckman Coulter Inc., and Thermo Fisher Scientific.

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Read the original:
Biobanks Market Projected to be Resilient During 2025 Owned - Owned

In the clinic for Aug. 6, 2020 | 2020-08-06 – BioWorld Online

By adminAugust 6, 2020Stem Cell Clinic

Company Product Description Indication Status Phase I Dicerna Pharmaceuticals Inc., of Lexington, Mass. RG-6346 RNAi targeting hepatitis B virus mRNA Chronic hepatitis B virus infection In group C, 9 of 10 participants who received RG-6346 and a nucleoside analogue and completed the treatment period achieved 1 log10 IU/mL reduction in hepatitis B surface antigen (HBsAg) at day 112; mean reduction in HBsAg at day 112 was 1.39 log10 IU/mL for the 1.5-mg/kg dose, 1.80 log10 IU/mL for the 3-mg/kg dose and 1.84 log10 IU/mL for the 6-mg/kg dose Dicerna Pharmaceuticals Inc., of Lexington, Mass. Nedosiran RNAi targeting lactate dehydrogenase Primary hyperoxaluria 1, 2 and 3 (PH1, PH2 and PH3) In the Phyox3 open-label extension, 8 of 8 patients with PH1 achieved normalization or near-normalization urinary oxalate levels (Uox) at day 120 with a mean Uox of 0.404 mmol/1.73m2 BSA/24 hr; 1 of 3 patients with PH2 achieved normalization of Uox Personalized Stem Cells Inc., of Poway, Calif. PSC-01 Adipose-derived stromal vascular fraction cells Knee osteoarthritis Completed enrollment in the study; data expected by the end of 2020 Precigen Triple-Gene, a unit of Precigen Inc., of Germantown, Md. INXN-4001 Nonviral plasmid expressing SDF-1alpha, VEGF165 and S100A1 Chronic heart failure Half of the 10 patients had a 5-point improvement in their total KCCQ score 6 months after treatment; 4 of 8 evaluable patients had a >50-meter improvement in their 6-minute walk time at 6 months Tessa Therapeutics Pte Ltd., of Singapore CD30 CAR T Autologous cell therapy Relapsed/refractory Hodgkin lymphoma For the 41 patients, 1-year survival was 94% in phase I/II study; of patients with complete responses, 61% had no evidence of recurrence after 1 year Phase II Bioaegis Therapeutics Inc., of Morristown, N.J. rhu-pGSN Recombinant human plasma gelsolin Hospitalized patients with severe COVID-19 pneumonia Enrolled first patient in study testing 3 doses of the drug; primary endpoint is survival without organ failure and without mechanical ventilation, vasopressors or dialysis on day 14 Idorsia Pharmaceuticals Japan, unit of Idorsia Ltd, of Allschwil, Switzerland Daridorexant Dual orexin receptor antagonist Insomnia In dose-confirmation study in 47 adults in Japan, study drug showed dose-dependent decrease in wake after sleep onset (WASO) at day 1 and 2 and decreased latency to persistent sleep in dose-dependent manner; improvements seen on measures such as subjective WASO, subjective latency to sleep onset and subjective total sleep time Medicinova Inc., of La Jolla, Calif. Ibudilast (MN-166) Phosphodiesterases 4 and 10 inhibitor Alcohol use disorder Drug reduced the number of heavy drinking days compared to placebo (p=0.03) and attenuated alcohol cue-elicited activation in the bilateral ventral striatum (p=0.02) Nordic Nanovector ASA, of Oslo, Norway Betalutin CD37-targeting antibody-radionuclide conjugate Relapsed/refractory follicular lymphoma Independent review committee recommended company focus on the 15-MBq/kg Betalutin dosage arm and discontinue the 20-MBq/kg dose Phase III Boehringer Ingelheim International GmbH, of Ingelheim, Germany Ofev (nintedanib) Tyrosine kinase inhibitor Chronic fibrosing interstitial lung diseases with a progressive phenotype In the Inbuild study, at 52 weeks, 43.4% of patents taking Ofev had a >5% absolute decline in forced vital capacity (FVC), compared to 55% of patients taking placebo; >10% FVC was seen in 28.3% and 36.6% of patient taking Ofev and placebo, respectively Levo Therapeutics Inc., of Chicago LV-101 (intranasal carbetocin) Oxytocin-receptor agonist Prader-Willi syndrome Primary endpoint for the 9.6-mg dose of LV-10 was not met; 3.2-mg dose improved the Hyperphagia Questionnaire for Clinical Trials (HQ-CT) score (p=0.016); HQ-CT scores for combined doses produced a p-value of 0.055; 3.2-mg dose also improved clinical global impression of change (p=0.027) and the PWS Anxiety and Distress Behaviors Questionnaire (p=0.027) Novartis AG, of Basel, Switzerland Ofatumumab Monoclonal antibody targeting CD20 Relapsing forms of multiple sclerosis Data published in The New England Journal of Medicine showed drug reduced annualized relapse rate by 51% and 58% compared to teriflunomide in the Asclepios I and II studies, respectively (p<0.001 for both); drug reduced risk of confirmed disability worsening at 3 months by 34% (p=0.002) and at 6 months by 32% (p=0.01) Rafael Pharmaceuticals Inc., of Cranbury, N.J. CPI-613 (devimistat) Targets the mitochondrial tricarboxylic acid cycle Metastatic pancreatic cancer Completed target enrollment of 500 patients in the Avenger 500 study

Notes

For more information about individual companies and/or products, see Cortellis.

Training neural circuits early in development improves response, study finds – University of Illinois News

By adminAugust 6, 2020Stem Cell Medicine

CHAMPAIGN, Ill. When it comes to training neural circuits for tissue engineering or biomedical applications, a new study suggests a key parameter: Train them young.

Techniques for training engineered neural circuits usually involve training them after the cells have fully matured. Using light-sensitive neurons derived from mouse stem cells, researchers at the University of Illinois, Urbana-Champaign found that training them throughout early cell development and network formation led to lasting improvements in the connections, responsivity and gene expression of the resulting neural network. They published their results in the journal Scientific Reports.

Its like an old dog learning new tricks versus a young puppy, said graduate student Gelson Pagan-Diaz, the first author of the study. When were training a network, if we stimulate it when its still like a puppy, we can get a better response to the training than if it were already mature.

Improved neural training has many applications in bioengineering and regenerative medicine. For example, the Illinois team hopes to use trained neural circuits to control the movement and behavior of miniature bio-hybrid machines. The types of improvements yielded by early training could give the machines and circuits more functionality and give the researchers more precise control over those functions.

As we advance the field of building machines with living cells, being able to stimulate and program neuronal cells and networks with light early in their development could be an important tool in our engineering repository, said study leader Rashid Bashir, a professor of bioengineering and dean of the Grainger College of Engineering at Illinois. Furthermore, this work could have implications for developmental biology, regenerative medicine and brain research.

To train the neurons, the researchers used timed pulses of light to stimulate the cells. The researchers began the training regimen when the cells were early in their development clusters of stem cells, called embryoid bodies, primed to become motor neurons. They continued the training as the cells differentiated, becoming fully mature neurons, and further continued it after transferring the cells to plates to connect and form neural circuits.

They then compared the early trained circuits with those cultured first and trained later the usual method.

The researchers saw a number of differences between the groups, Pagan-Diaz said. In the neurons trained during development, they saw more extensions indicating connections between cells, an increase in neurotransmitter packages sent between cells, and more structured nerve firing, indicating greater network stability. The effects of the early training were long-lasting, whereas cells trained later tended to have transient responses.

You can think of the neurons being like athletes in training, Pagan-Diaz said. The light stimulation was like a regular workout for the neurons they were stronger and more athletic, and did their jobs better.

To determine the underlying basis for these changes, the researchers analyzed the neurons genetic activity. They saw an increase in gene expression for genes related to network maturity and neural function, indicating that the early training could have permanently altered genetic pathways as the cells developed, Bashir said.

The researchers are continuing to explore what kinds of activities could be enhanced or programmed by early neuron training in the embryoid body phase. Embryoid bodies could be useful building-block components for biological machines, Pagan-Diaz said, and also hold promise for regenerative medicine.

Previous studies have shown that embryoid bodies with motor neurons implanted into mice that had been injured could improve the regeneration of tissue, Pagan-Diaz said. If we can improve or enhance the functionality of these embryoid bodies prior to putting them into an injured model, then theoretically we could enhance the recovery beyond what has been seen with injecting them and then stimulating them later.

The National Science Foundation supported this work through the Emergent Behaviors of Integrated Cellular Systems science and technology center and through the Miniature Brain Machinery Research Traineeship. Research staffer Jenny Drnevich, graduate students Karla Ramos-Cruz and Richard Sam, and University of Illinois, Chicago bioengineering professor Perijat Sengupta were co-authors of the paper.

See more here:
Training neural circuits early in development improves response, study finds - University of Illinois News

Cord blood offers hope for rare diseases and ethnic minorities – The Province

By adminAugust 6, 2020Stem Cell Medical Center

A different combination of chemotherapy drugs together with umbilical cord blood may result in a safer, more universal treatment for a variety of genetic disorders. emarys / iStock / Getty Images Plus

Researchers at the University of Pittsburgh Medical Centre may have developed an innovative method of transplanting stem cells, resulting in a safer, universal treatment for a variety of genetic disorders. Through combining this approach with umbilical cord blood, treatment is also more accessible to ethnic minorities, a demographic that historically has had difficulties accessing bone marrow transplants.

The study, published in Blood Advances and the largest of its kind to date, used umbilical cord blood to treat 44 children with varying non-cancerous diseases. Umbilical cord blood is a potent source of hematopoietic stem cells cells that are able to form red and white blood cells in the patients. Due to their ability to develop into different types of cells, this treatment can be used to address many different types of disorders.

We wanted to offer a uniform concept to a wide array of diseases, said Dr. Paul Szabolcs, the Chief of Bone Marrow Transplantation and Cellular Therapies at UPMC Childrens Hospital and principal author of the study. We successfully reduced the intensity of chemotherapy and nevertheless, we were still able to engraft all our patients.

Typically, before receiving a stem cell graft (either umbilical cord blood or bone marrow) patients undergo an intense round of chemotherapy to kill off the patients own immune system and allow the new cells to grow. This method is effective but damaging to the body. For patients who do not have cancer and are pursing this treatment to improve the quality of their life (versus saving their life), the risks may simply be too high.

The approach developed by the team at the Pittsburgh Medical Centre uses a different combination of chemotherapy drugs, which are not as potent to the body. The goal of this approach is not to kill every cell in the patients bone marrow, but to make enough room for the new cells to flourish.

We successfully reduced the intensity of chemotherapy and we were still able to engraft all our patients, says Szabolcs. Using maximum intensity, you might be inadvertently killing patients and causing irreversible organ disease. [We used] use reduced intensity and have excellent survival.

This more moderate procedure is promising for conditions where the standard intensity regime poses a barrier to bone marrow or cord blood transfusions. More than half of the patients in the study had a form of leukodystrophy a genetic disorder that leads to the destruction of the protective coating of the nerves in the brain and spinal cord, according to the National Organization for Rare Disorders.

Three year survival rate after the standard chemotherapy preparation for umbilical cord blood transfusions for individuals with leukodystrophies ranges from 49 per cent to 77 per cent depending on their health at the time of the transfusion. The reduced-intensity approach reported a three year survival rate of 94 per cent.

The stem cells in umbilical cord blood provide a promising treatment as recipients do not have to have a perfect HLA (immune profile) match with the donor.

About 70 per cent of patients who need stem cells or bone marrow transplants have to rely on an unrelated donor to find a match, according to the University of British Columbia Medical Journal. This can create accessibility concerns for ethnic minorities. A 2012 study calculated that match rates for unrelated donors ranges from two per cent for POC to 46 per cent for Caucasians.

Since 2012, Canadian Blood Services has extended campaigns to communities with low match rates to increase the presence of donors. The concern still remains, however. Cord blood offers a hopeful alternative.

Its really applicable for ethnic minorities where the perfect HLA match might be elusive in the living donor population, says Szabolcs. And cord blood is readily available.

emjones@postmedia.com |@jonesyjourn

Dont miss the latest on COVID-19, reopening and life. Subscribe to Healthings daily newsletterComing Out of COVID.

National STEM Scholars Announced for 2020 – PR Web

By adminAugust 6, 2020Stell Cell Research

The 2020 Class of National STEM Scholars convened at Gatton Academy at WKU this week

LOUISVILLE, Ky. (PRWEB) August 06, 2020

Nine middle school teachers from eight states have been selected to participate in the prestigious National STEM Scholar Program, a unique professional development program that provides advanced STEM (science, technology, engineering and math) training, national network building, and project support for middle school science teachers nationwide.

Created in partnership between the National Stem Cell Foundation and The Gatton Academy of Mathematics and Science at Western Kentucky University (WKU), the National STEM Scholar Program selects ten teachers each year from a national pool of applicants based solely on the description of a Challenge Project the applicant would implement if funds were not a barrier to execution. Selected projects are chosen for maximum impact in the middle school classrooms where research shows lifelong STEM career decisions are being made. STEM Scholars convene on WKUs campus for a week of advanced STEM training and finalize their Challenge Projects with input from their National STEM Scholar class colleagues. Each Scholar is provided access to a generous stipend for the technology and supplies they need to implement their Challenge Projects at home.

The 2020 National STEM Scholar class will be hosted by The Gatton Academy August 4 - 9 on the campus of WKU in Bowling Green, KY. Selected from approximately 200 applicants across the country, the 2020 National STEM Scholars are:

Dr. Paula Grisanti, CEO of the National Stem Cell Foundation, said, Through our work with researchers and scientists nationwide, we became aware of the widening gap between 21st Century jobs and the U.S. STEM-educated graduates who can fill them. We added education to our mission in 2015 as a way to support the development of a new generation of scientists working to advance technology, build infrastructure and find cures for diseases and conditions that affect us all. Supporting teachers who inspire and motivate middle school students at this critical decision-making age will directly impact how many choose to pursue STEM skills that are essential for 21st Century jobs. By investing in the influential middle school STEM teacher now, we reach thousands of students in classrooms today and far into the future.

Dr. Julia Link Roberts, Executive Director of The Gatton Academy, added, This partnership will accrue benefits for the National STEM Scholars, middle school students in their classrooms, and the middle school science teachers with whom they collaborate. The National STEM Scholar Program is an excellent way for teachers to learn new strategies and new ways to engage students to help them become and stay interested in science and math.

To date, National STEM Scholars represent 49 middle schools in 26 states, from Alaska to New York and Wisconsin to Florida. A significant requirement of selection is the commitment to share lessons learned with colleagues in the Scholars home schools, districts or states, magnifying impact over multiple classrooms and years.

About the National Stem Cell Foundation The National Stem Cell Foundation is a 501(c)3 non-profit organization that funds adult stem cell and regenerative medicine research, connects children with limited resources to clinical trials for rare diseases and underwrites the National STEM Scholar Program for middle school science teachers inspiring the next generation of STEM (science, technology, engineering and math) pioneers nationwide. For more information, visit http://www.nationalstemcellfoundation.org.

About The Gatton Academy Established in 2007, The Gatton Academy of Mathematics and Science is Kentuckys first state-supported, residential program for high school students with interests in advanced math and science careers. One of only 15 such programs in the nation, The Academy has been named to The Washington Posts list of top-performing schools with elite students for eight consecutive years. For more information, visit http://www.wku.edu/academy.

Share article on social media or email:

See the rest here:
National STEM Scholars Announced for 2020 - PR Web

US government considers ethics of aborted tissue research – Catholic News Agency

By adminAugust 6, 2020Stell Cell Research

Washington, D.C. Newsroom, Aug 6, 2020 / 12:00 pm MT (CNA).- A new federal ethics advisory board for fetal tissue research has convened to consider future federally-funded research proposals that involve tissue from aborted babies.

The Human Fetal Tissue Research Ethics Advisory Board of the National Institutes of Health (NIH) met for the first time on July 31, to advise the Health Secretary on the ethics of research proposals involving fetal tissue of aborted babies.

The board was first announced in June of 2019, when the Trump administration decided to halt new research with aborted fetal tissue at NIH facilities, and limited funding of such research conducted outside the NIH.

For the research conducted outside the NIH, or extramural research, the administration announced that an ethics advisory board would be appointed to consider such funding and advise the secretary of Health and Human Services (HHS) on the proposals.

Some researchers have called for the administration to end its moratorium, saying that research with aborted fetal tissue could be vital to developing treatments and a cure for the new coronavirus (SARS-CoV-2).

In February, the HHS announced that it would begin accepting nominations to the board, and during that time period, some researchers at an NIH research laboratory told the Washington Post that the administrations moratorium on fetal tissue research was hindering possible advances in research on treatments for the coronavirus.

Dr. David Prentice, now a member of the NIH Human Fetal Tissue Research Ethics Advisory Board, told CNA in March that the timing of the comments was peculiar as it could have been related to the consideration of appointments to the board.

Several leading coronavirus vaccine candidates are using cell lines from aborted babies, including some funded by the U.S.; other candidates have been determined to be ethically uncontroversial by the pro-life Charlotte Lozier Institute.

One candidate in particularbeing developed by Moderna and the National Institute of Allergy and Infectious Diseasesis not using fetal cell lines directly in production, but is based on research that involved aborted fetal cell lines. As Moderna was not involved in that research, CLI said that the vaccine candidate is ethically uncontroversial.

The NIH ethics board members are appointed for a duration that lasts as long as the board is convened; the boards charter says that [t]he estimated annual person-years of staff support required is 0.7. Appointments to the board are made by the HHS secretary.

Heading the advisory board is Paige Cunningham, interim president of Taylor University, an evangelical Christian university in Indiana.

Several Catholic bioethicists are on the board, including Fr. Tadeusz Pacholczyk, director of education at the National Catholic Bioethics Center. The co-chair of the Catholic Medical Association (CMA) ethics committee, Greg Burke, is a member, along with CMA member Dr. Ashley Fernandes of the Ohio State University medical school.

The pro-life Charlotte Lozier Institute (CLI) is also represented on the board, with CLI vice president Dr. David Prentice and associate scholars Ingrid Skop and Maureen Condic as members.

Some board members, such as Dr. Lawrence Goldstein of the University of California San Diego, support fetal tissue research; he called cell lines from fetal tissue critical in vaccine development, along with stem cell research and the use of humanized mice to develop immune cell-forming tissues.

Two members testified in 2016 before the House select investigative panel of the Energy and Commerce Committee, in a hearing on bioethics and fetal tissue.

Cunningham said at the hearing that [t]he fetus is a human subject entitled to the protections that both traditional and modern codes of medical ethics provide to human subjects.

Kevin Donovan, MD, director of the Pellegrino Center for Clinical Bioethics at Georgetown University Medical Center, also testified, noting the current moral ambiguity in the nations discourse on abortion.

We have decided that we can legally abort the same fetus that might otherwise be a candidate for fetal surgery, even using the same indications as justification for acts that are diametrically opposed, he said. We call it the fetus if it is to be aborted and its tissues and organs transferred to a scientific lab. We call it a baby, even at the same stage of gestation, when someone plans to keep it and bring it into their home.

If we cannot act with moral certainty regarding the appropriate respect and dignity of the fetus, we cannot morally justify its destruction, he said.

During the public portion of the July 31 meeting, board members were introduced and then heard from several researchers who were either in support of or in opposition to research using fetal tissue from elective abortions.

The 2008 Vatican document Dignitatis Personae addressed the topic of aborted fetal tissue research, saying that there is a duty to refuse to use such biological material even when there is no close connection between the researcher and the actions of those who performed the artificial fertilization or the abortion, or when there was no prior agreement with the centers in which the artificial fertilization took place.

This duty springs from the necessity to remove oneself, within the area of ones own research, from a gravely unjust legal situation and to affirm with clarity the value of human life, the Congregation for the Doctrine of the Faith document stated.

Read this article:
US government considers ethics of aborted tissue research - Catholic News Agency

Cell Viability Assays Market by Production Analysis, Current Trends 2024 Analysis of Regions with Top vendors, Market Dynamics, Types, Applications,…

By adminAugust 6, 2020Stell Cell Research

Market Challenge: Threats in major regions

Cell Viability Assays Market Report Highlights:

For More Information or Query or Customization Before Buying, Visit at https://www.industryresearch.co/enquiry/pre-order-enquiry/15398351

Cell Viability Assays Market Segmentation Covers:

Product: o Consumables

o Instruments

Regional Segmentation:

The objective of Studies:

Purchase this Report (Price 2500 USD for single-user license) https://www.industryresearch.co/purchase/15398351

Some Points from Cell Viability Assays Market Report TOC:

PART01:EXECUTIVESUMMARY

PART02:SCOPEOFTHEREPORT

PART03:MARKETLANDSCAPE

PART04:MARKETSIZING

PART05:FIVEFORCESANALYSIS

PART06:MARKETSEGMENTATIONBYTECHNOLOGY

PART07:MARKETSEGMENTATIONBYFURNACETYPE

PART08:CUSTOMERLANDSCAPE

PART09:GEOGRAPHICLANDSCAPE

PART 10: DRIVERS AND CHALLENGES

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

PART 13: VENDOR ANALYSIS

For Detailed TOC Click Here

Name: Ajay More

Phone: US +14242530807/ UK +44 20 3239 8187

Email: [emailprotected]

Our Other Reports:

Nanomaterials in Cosmetic and Personal Care Market Growth Size, Share 2020 | Industry Analysis with COVID-19 Impact, Company Overview, Key Countries with Future Prospect to 2026

Needle-Free IV Connectors Market Size Outlook 2020 to 2025: Market Trends, Segmentation, Growth Rate and Competitive Landscape with COVID-19 Outbreak

Automated Material Handling and Storage System Market 2020| Worldwide Overview by Industry Size, Market Share, Future Trends, Growth Factors and Leading Players Research Report Analysis till 2025

Non-dairy Creamer Fats Market Growth Trends with Key Players 2020 Size by Regions, Global Industry Share, Sales Revenue and Opportunities till 2026 with COVID-19 Impact

Petroleum Jellies Market 2020 Global Industry Size Estimation, Research Update, Future Scope, Revenue, Pricing Trends, Growth Opportunity, Regional Outlook and Forecast to 2025

Toy Balloon Market Size | Share Forecast 2020 to 2026: Competition Analysis, Industry Growth by New Innovations, Top Players Analysis with COVID-19 Impact

Here is the original post:
Cell Viability Assays Market by Production Analysis, Current Trends 2024 Analysis of Regions with Top vendors, Market Dynamics, Types, Applications,...

New Report: Regenerative Medicine & Advanced Therapies Sector Thriving Despite COVID-19 – GlobeNewswire

By adminAugust 6, 2020Stem Cell Medicine

August 06, 2020 09:00 ET | Source: Alliance for Regenerative Medicine

Cell, Gene & Tissue-Based Therapy Developers Poised to Break Year-Over-Year Global Financing Records

WASHINGTON, D.C., Aug. 06, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE --The Alliance for Regenerative Medicine (ARM), the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies, today announces the publication of its H1 2020 Global Sector Report, Innovation in the Time of COVID-19. The report provides an in-depth look at trends and metrics in the gene, cell, and tissue-based therapeutic sector in the midst of the pandemic.

As the voice of the sector globally, ARM regularly publishes sector data reports to showcase clinical and scientific progress, as well as advancements and remaining challenges in the policy environment surrounding cell, gene and tissue-based therapies. The report also includes updated metrics on fundraising and clinical trials from more than 1,000 therapeutic developers worldwide.

Highlights from the H1 2020 Global Sector Report include:

Janet Lambert, CEO of ARM, commented:The regenerative medicine and advanced therapy sector has shown remarkable resilience in the face of many new challenges posed by COVID-19. Most importantly, were continuing to see patients benefit from the profound therapeutic effects of both approved products and those currently in clinical development. ARM will continue to work with our membership and with policymakers in the second half of 2020 to further advance these transformative technologies. We are committed to bringing these life-changing therapies to patients in need.

This report is the latest in ARMs series of global regenerative medicine sector reports, providing up-to-date metrics on financings and the clinical landscape, as well as expert commentary on key trends and progress in the field. The full report is availableonline here, with key sector metrics and infographicsavailable here. For more information, please visitwww.alliancerm.orgor contact Kaitlyn (Donaldson) Dupont atkdonaldson@alliancerm.org.

About the Alliance for Regenerative Medicine

The Alliance for Regenerative Medicine (ARM) is the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies. ARM promotes legislative, regulatory and reimbursement initiatives to advance this innovative and transformative sector, which includes cell therapies, gene therapies and tissue-based therapies. Early products to market have demonstrated profound, durable and potentially curative benefits that are already helping thousands of patients worldwide, many of whom have no other viable treatment options. Hundreds of additional product candidates contribute to a robust pipeline of potentially life-changing regenerative medicines and advanced therapies. In its 11-year history, ARM has become the voice of the sector, representing the interests of 360+ members worldwide, including small and large companies, academic research institutions, major medical centers and patient groups. To learn more about ARM or to become a member, visithttp://www.alliancerm.org.

Excerpt from:
New Report: Regenerative Medicine & Advanced Therapies Sector Thriving Despite COVID-19 - GlobeNewswire